Identification of ap80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4b

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3399-3410

  Dufner Beattie, Jodi ^a   O'Guin, Andrew ^a   O'Guin, Stephanie ^a   Briley, Aaron ^a   Wang, Bin ^a   Balsarotti, Jennifer ^a   Roth, Robert ^a   Starkey, Gale ^a   Slomczynska, Urszula ^a   Noueiry, Amine ^a   Olivo, Paul D ^a   Rice, Charles M ^b  

^a Apath LLC   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHYLCYTIDINE; ANTIVIRUS AGENT; AP 80978; AP 89652; CYCLOSPORIN A; NONSTRUCTURAL PROTEIN 4B; SMALL MOLECULE TRANSPORT AGENT; TELAPREVIR; UNCLASSIFIED DRUG; 2'-C-METHYLADENOSINE; ADENOSINE; AP80978; CYCLOSPORIN; FURAN DERIVATIVE; NS4B PROTEIN, FLAVIVIRUS; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; RENILLA LUCIFERIN 2 MONOOXYGENASE; THIOPHENE DERIVATIVE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HEPATITIS C; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; REPLICON; SITE DIRECTED MUTAGENESIS; VIRAL CLEARANCE; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOASSAY; CELL CULTURE TECHNIQUE; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HIGH THROUGHPUT SCREENING; VIROLOGY;

ADENOSINE; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL CULTURE TECHNIQUES; CELL LINE; CELL SURVIVAL; CYCLOSPORINE; FURANS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUCIFERASES, RENILLA; MUTAGENESIS, SITE-DIRECTED; OLIGOPEPTIDES; PYRIDINES; REPLICON; THIOPHENES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84901277747     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00113-14     Document Type: Article

References (46)

1. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837-849. http://dx.doi.org/10.1038/nm.3248.
2. Hajarizadeh B, Grebely J, Dore GJ. 2013. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 10:553-562. http://dx.doi.org/10.1038/nrgastro.2013.107.
3. Schinazi R, Halfon P, Marcellin P, Asselah T. 2014. HCV direct-Acting antiviral agents: the best interferon-free combinations. Liver Int. 34(Suppl 1):69-78. http://dx.doi.org/10.1111/liv.12423.
4. Wasley A, Alter MJ. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:1-16. http://dx.doi.org/ 10.1055/s-2000-9506.
5. Kenny-Walsh E. 2001. The natural history of hepatitis C virus infection. Clin. Liver Dis. 5:969-977. http://dx.doi.org/10.1016/S1089-3261(05) 70204-X.
6. Alter HJ, Seeff LB. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20:17-35. http://dx.doi.org/10.1055/s-2000-9505.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitisCvirus infection. N. Engl. J. Med. 347:975-982. http://dx.doi.org/10.1056/NEJMoa020047.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. http://dx.doi.org/10.1016/S0140-6736(01)06102-5.
9. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa 1010494.
10. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
11. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. 2012. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl 1):S88-S100. http://dx.doi.org/10.1016/S0168-8278(12)60010-5.
12. Gentile I, Borgia F, Coppola N, Buonomo AR, Castaldo G, Borgia G. 2014. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr. Med. Chem. 21:1391-1404. http://dx.doi.org/10.2174/ 0929867321666131228222215.
13. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. 2014. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146:420-429. http://dx.doi.org/10.1053/j.gastro.2013.10.057.
14. Koff RS. 2014. The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment. Pharmacol. Ther. 39:478-487. http://dx.doi.org/10. 1111/apt.12601.
15. Dalinger IL, Vatsadse IA, Shevelev SA, Ivachtchenko AV. 2005. Liquidphase synthesis of combinatorial libraries based on 7-trifluoromethylsubstituted pyrazolo[1,5-A]pyrimidine scaffold. J. Comb. Chem. 7:236-245. http://dx.doi.org/10.1021/cc049855o.
16. Slomczynska U, Olivo P, Beattie J, Starkey G, Noueiry A, Roth R. 2010. Compounds, compositions and methods for control of hepatitis C viral infections. World Intellectual Property Organization patent WO2010096115.
17. Slomczynska U, Olivo P, Beattie J, Starkey G, Noueiry A, Roth R. July 2011. Compounds, compositions, and methods for control of hepatitis C viral infections. US patent 20110262397 A1.
18. Gilbert BE, Knight V. 1986. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30:201-205. http://dx.doi.org/10.1128/ AAC.30.2.201.
19. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288. http://dx.doi.org/10.1053/jhep.2003.50449.
20. Eldrup AB, Prhavc M, Brooks J, Bhat B, Prakash TP, Song Q, Bera S, Bhat N, Dande P, Cook PD, Bennett CF, Carroll SS, Ball RG, Bosserman M, Burlein C, Colwell LF, Fay JF, Flores OA, Getty K, LaFemina RL, Leone J, MacCoss M, McMasters DR, Tomassini JE, Von Langen D, Wolanski B, Olsen DB. 2004. Structure-Activity relationship of heterobase- modified 2-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 47:5284-5297. http://dx.doi.org/10.1021/jm040068f.
21. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190. http://dx.doi.org/10.1128/JVI.77.5.3181-3190.2003.
22. Noueiry AO, Olivo PD, Slomczynska U, Zhou Y, Buscher B, Geiss B, Engle M, Roth RM, Chung KM, Samuel M, Diamond MS. 2007. Identification of novel small-molecule inhibitors of West Nile virus infection. J. Virol. 81:11992-12004. http://dx.doi.org/10.1128/JVI.01358-07.
23. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, Gubler DJ. 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230:300-308. http://dx.doi.org/10.1006/viro.1997.8500.
24. Malykhina O, Yednak MA, Collins PL, Olivo PD, Peeples ME. 2011. A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression. J. Virol. 85:4792-4801. http://dx.doi.org/10. 1128/JVI.02399-10.
25. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. 1999. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73: 2333-2342.
26. Agapov EV, Frolov I, Lindenbach BD, Pragai BM, Schlesinger S, Rice CM. 1998. Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc. Natl. Acad. Sci. U. S. A. 95:12989-12994. http://dx.doi.org/10.1073/pnas. 95.22.12989.
27. Lutz A, Dyall J, Olivo PD, Pekosz A. 2005. Virus-inducible reporter genes as a tool for detecting and quantifying influenza A virus replication. J. Virol. Methods 126:13-20. http://dx.doi.org/10.1016/j.jviromet.2005.01.016.
28. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/ science.290.5498.1972.
29. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413. http://dx.doi.org/10.1073/pnas.0504877103.
30. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76:5974-5984. http://dx.doi.org/10.1128/JVI.76.12.5974-5984.2002.
31. Piccininni S, Varaklioti A, Nardelli M, Dave B, Raney KD, McCarthy JE. 2002. Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. J. Biol. Chem. 277:45670-45679. http://dx.doi.org/10.1074/jbc.M204124200.
32. Kato J, Kato N, Yoshida H, Ono-Nita SK, Shiratori Y, Omata M. 2002. Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo. J. Med. Virol. 66:187-199. http://dx.doi.org/10.1002/jmv.2129.
33. He Y, Yan W, Coito C, Li Y, Gale M, Jr, Katze MG. 2003. The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins. J. Gen. Virol. 84: 535-543. http://dx.doi.org/10.1099/vir.0.18658-0.
34. Florese RH, Nagano-Fujii M, Iwanaga Y, Hidajat R, Hotta H. 2002. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res. 90:119-131. http://dx.doi.org/10.1016/S0168- 1702(02)00146-6.
35. Einav S, Elazar M, Danieli T, Glenn JS. 2004. A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. J. Virol. 78:11288-11295. http://dx.doi.org/10.1128/JVI.78.20.11288-11295.2004.
36. Koch JO, Bartenschlager R. 1999. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J. Virol. 73:7138-7146.
37. Neddermann P, Clementi A, De Francesco R. 1999. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J. Virol. 73:9984-9991.
38. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. 2008. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat. Biotechnol. 26: 1019-1027. http://dx.doi.org/10.1038/nbt.1490.
39. Rai R, Deval J. 2011. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res. 90:93-101. http://dx.doi.org/10.1016/ j.antiviral.2011.01.009.
40. Chunduru SK, Benatatos CA, Nitz TJ, Bailey TR. November 2007. Compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases. US patent US2007/ 0269,420.
41. Cho NJ, Dvory-Sobol H, Lee C, Cho SJ, Bryson P, Masek M, Elazar M, Frank CW, Glenn JS. 2010. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci. Transl. Med. 2:15ra16. http://dx.doi.org/10.1126/scitranslmed.3000331.
42. Bryson PD, Cho NJ, Einav S, Lee C, Tai V, Bechtel J, Sivaraja M, Roberts C, Schmitz U, Glenn JS. 2010. A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Res. 87: 1-8. http://dx.doi.org/10.1016/j.antiviral.2010.03.013.
43. Gu Z, Graci JD, Lahser FC, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, Peltz SW, Tong X, Ralston R, Colacino JM. 2013. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C virus NS4B protein. Antimicrob. Agents Chemother. 57:3250-3261. http://dx.doi.org/10.1128/ AAC.00527-13.
44. Jones DM, Patel AH, Targett-Adams P, McLauchlan J. 2009. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J. Virol. 83:2163-2177. http://dx.doi.org/10. 1128/JVI.01885-08.
45. Paul D, Romero-Brey I, Gouttenoire J, Stoitsova S, Krijnse-Locker J, Moradpour D, Bartenschlager R. 2011. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J. Virol. 85:6963-6976. http://dx.doi.org/10.1128/ JVI.00502-11.
46. Han Q, Manna D, Belton K, Cole R, Konan KV. 2013. Modulation of hepatitis C virus genome encapsidation by nonstructural protein 4B. J. Virol. 87:7409-7422. http://dx.doi.org/10.1128/JVI.03523-12.